Ind-Swift Laboratories Ltd Company History

the board has approved the issue of 2322750 Equity shares upon conversion of preference shares into equity shares capital to the followings: -

1. 1870375 equity shares to promoters at the rate of Rs 32/- per share

2. 452375 equity share to other bodies corporate at the rate of Rs 32/- per share.

Ind-Swift Laboratories Ltd. has informed that the company has received an intimation from Ind-Swift Ltd., the promoter company that it has disinvested 386930 equity shares (2.48%) of the company and the present holding of Ind-Swift Limited is 22,57,970 equity shares of Rs. 10/- each (14.46%).

Sets up subsidiary in US

Ind-Swift Laboratories shifts corporate and head office from SCO 813, Shivalik Enclave, Nac, Manimajra, Chandigarh - 160101 to SCO 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160101

Ind Swift Laboratories Ltd gets achievement award for the Best Performing Company in Category E by the Express Pharma Pulse for the year 2004.

Ind Swift Laboratories enters into long term agreements for supply of APIs

Ind Swift Laboratories wins Deloitte Fast 500 Award 2004 in HongKong

Ind Swift Laboratories puts three new units to operation.

The Company has recommended a dividend of 15%.

Ind Swift Laboratories inaugurates its state of art R&D centre.

Ind-Swift Labs opens R&D centre in Mohali.

The Company has recommended a Dividend of 15% (Rs 1.50 per Share) on the equity shares of the Company and Re 1/- per share on the preference shares of the Company.

Chandigarh-based Ind Swift Laboratories Ltd has got the Bhartiya Udyog Rattan Award for its contribution to society and national development, given by the National Education and Human Resource Development Organisation, a national social charitable organisation for National development, last week in Mumbai. Maharashtra Education Minister Vasant Purake gave the award to O P Thapliyal, HR head of the company.

Ind Swift Laboratories Ltd has informed that the Company has successfully completed USFDA inspection for Clarithromycin, Active Pharmaceutical Ingredient (API) manufacturing facility. Ind-Swift Laboratories Inc USA (ISL INC.), a wholly owned subsidiary of the Company was instrumental in achieving this milestone, said N R Munjal, Managing Director.

The Company at its meeting held on July 30, 2007, inter alia, has recommended a dividend of 10% on the Equity Shares of the Company.

The Board has recommended a dividend of 10% on the Equity Shares of the Company.

Ind-Swift Laboratories Ltd - Change in Board of Directors

1) Sh. S.R. Mehta has been nominated as the Chairman of the Company.

2) Sh. N.R. Munjal has been nominated as the Vice-Chairman of the Company.

3) Sh. V.K. Mehta has been nominated as the Managing Director of the Company.

Registered Office of the Company has been shifted From SC0 493-94, Sector 35-C, Chandigarh - 166022 To SCO 850, Shivalik Enclave ,NAC, Manimajra, Chandigarh - 160101.

The Board has recommended a dividend of 10% on the Equity Shares of the Company.

The Company at its meeting held on March 24, 2009, have appointed the following as Independent Directors with immediate effect: 1. Mr. H P S Chawla 2. Mr. N D Aggarwal. 3. Mrs. Nirmal Aggarwal.

The Board recommended a dividend of Rs. 1/ per share of Rs. 10/- each.

Ind-Swift Laboratories Ltd has informed BSE that the Board of Directors have appointed Dr. N. P. Singh as Independent Director with immediate effect.

Ind-Swift Laboratories Ltd has informed BSE regarding a Press Release dated September 23, 2011 titled " Ind-Swift Laboratories gets TGA approval from Australia for its seven APIs".

Ind-Swift Laboratories Ltd has informed BSE regarding a Press Release titled "Ind-Swift Labs files two more DMFS with USFDA".

The Board has recommended a dividend of Rs 1/- per share on Equity Shares of Rs.10/- each the Company.

nd-Swift Laboratories Ltd has informed BSE regarding a Press Release dated February 17, 2011 titled "Ind-Swift Laboratories gets PMDA Approval for Pioglitazone and Risedronate Sodium from Govt of Japan".

Ind-Swift Laboratories Ltd has informed BSE regarding a Press Release titled "Ind Swift Labs Bags First Order for Contract Research".

Ind-Swift Laboratories Ltd has informed BSE regarding a Press Release dated April 10, 2012 titled "Ind-Swift Labs gets USFDA for 5 APIs for its Derabassi facility".

Ind-swift, one of the leading pharmaceutical companies in India, known for its drug research and development, yesterday, announced that it has launched the generic formulations of the drug Atorvastatin in UK, in collaboration with Wockhardt UK Ltd., a pharmaceutical and biotechnology company.

Buoyed by the launching of Atorvastatin Tablets in UK, shares of drug making company Ind-Swift Ltd gained over 2 per cent on the Bombay Stock Exchange in early trading.

R K Ummat has been appointed as an Independent Director on the Board of the Company.

Dr. Vinay Kumar Arora has been appointed as an Independent Director w.e.f. March 31, 2014.

Acquisition of "KEC Bikaner Sikar Transmission Private Limited".

Ind-Swift Labs tied up with Reputed Generic player in USA To Launch Generic Fexofenadine.

Ind-Swift Laboratories Limited has received North India Best Employer Award''.